Patient-Reported Outcomes Following UGN-102 Treatment in Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: An Analysis of 3 Clinical Trials.
Max R. Kates, Victoria Tsurutis, Anagha Nadkarni, L Veronica Lee et autres
UGN-102 is a reverse thermal hydrogel formulation of mitomycin indicated for nonsurgical intravesical treatment of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC). This analysis evaluates patient-reported outcomes (PROs) for quality of life (QoL), functioning, and symptom burden across 3 late-phase clinical trials …
us (code pays fourni par la source)